IMAB News and Press, I-MAB From 08/17/23

2023-08-17 12:26:06 ET I-Mab (IMAB) Q2 2023 Earnings Call Transcript August 17 2023, 08:00 AM ET Company Participants Tyler Ehler - Senior Director for IR Raj Kannan - CEO John Hayslip - CMO Richard Yeh - Interim CFO and COO Andrew Zhu - President and Hea...

2023-08-17 06:16:20 ET I-Mab Biopharma press release ( NASDAQ: IMAB ): 1H Non-GAAP EPADS of -$1.05 misses by $0.26 . Revenue of $2.7M (-62.04% Y/Y) misses by $0.3M . As of June 30, 2023, the Company had cash, cash equivalents, restricted cash, and short-term in...

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates PR Newswire Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐ Givastomig ...

2023-08-16 14:34:07 ET I-Mab Biopharma ( NASDAQ: IMAB ) is scheduled to announce 1H earnings results on Thursday, August 17th, before market open. The consensus EPS Estimate is -$0.79 (+48.7% Y/Y) and the consensus Revenue Estimate is $3M (-61.2% Y/Y).Over the last 1 year, I...

2023-08-16 10:13:08 ET Major earnings expected before the bell on Thursday include: Bilibili ( BILI ) Lumentum Holdings ( LITE ) Nano-X Imaging ( NNOX ) Tapestry ( TPR ) Walmart ( WMT ) For further details see: Notable earnings before Thur...

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023 PR Newswire ROCKVILLE, Md. and SHANGHAI , Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company co...

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC PR Newswire GAITHERSBURG, Md. and SHANGHAI , July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to t...

2023-06-28 01:47:00 ET Summary I-Mab has appointed Raj Kannan as its new CEO, filling its top position 18 months after its last top executive quit. The new CEO is an industry veteran who engineered sales of his previous two companies after bringing their first drugs to market, hin...

2023-06-22 08:11:13 ET I-Mab ( NASDAQ: IMAB ) has announced the appointment of Mr. Raj Kannan as the Company's new CEO and a member of the board of directors effective June 22, 2023. This appointment serves as a significant step towards further realizing I-Mab's missi...

I-Mab Announces the Appointment of Raj Kannan as CEO PR Newswire GAITHERSBURG, Md. and SHANGHAI , June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, developme...